专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

31. 发明授权

EP3068389B1 COMPOUNDS INHIBITING LEUCINE-RICH REPEAT KINASE ENZYME ACTIVITY 有权转让
公开(公告)号：EP3068389B1
公开(公告)日：2019-10-02
申请号：EP14861985.1
申请日：2014-11-10
申请人： Merck Sharp & Dohme Corp.
发明人： DEMONG, Duane , MILLER, Michael , LIU, Hong , DAI, Xing , GRESHOCK, Thomas, J. , STAMFORD, Andrew , NARGUND, Ravi
IPC分类号： C07D231/56 , C07D401/14 , C07D401/04 , A61K31/415

33. 发明公开

EP3448417A1 INSULIN DIMER-INCRETIN CONJUGATES 审中-公开
公开(公告)号：EP3448417A1
公开(公告)日：2019-03-06
申请号：EP17790145.1
申请日：2017-04-21
申请人： Merck Sharp & Dohme Corp.
发明人： PALANI, Anandan , YANG, ZhiQiang , YAN, Lin , LIN, Songnian , HUO, Pei , NARGUND, Ravi
IPC分类号： A61K38/28 , A61P3/08

34. 发明授权

EP2753325B1 TETRACYCLIC HETEROCYCLE COMPOUNDS AND METHODS OF USE THEREOF FOR THE TREATMENT OF VIRAL DISEASES 有权转让
公开(公告)号：EP2753325B1
公开(公告)日：2018-09-19
申请号：EP12830590.1
申请日：2012-08-20
申请人： Merck Sharp & Dohme Corp. , MSD Italia S.r.l.
发明人： MCCOMAS, Casey Cameron , LIVERTON, Nigel J. , HABERMANN, Joerg , KOCH, Uwe , NARJES, Frank , LI, Peng , PENG, Xuanjia , SOLL, Richard , WU, Hao , PALANI, Anandan , HE, Shuwen , DAI, Xing , LIU, Hong , LAI, Zhong , LONDON, Clare , XIAO, Dong , ZORN, Nicolas , NARGUND, Ravi
IPC分类号： A61K31/343 , C07D307/82 , C07D405/10 , A61P31/14
CPC分类号： A61K31/553 , A61K31/407 , A61K31/437 , A61K31/519 , A61K31/5365 , A61K45/06 , C07D491/052 , C07D491/147 , C07D498/04 , C07D498/14 , C07D498/22 , Y02A50/387 , Y02A50/389 , Y02A50/395 , A61K2300/00
摘要： The present invention relates to compounds of formula (I) that are useful as hepatitis C virus (HCV) NS5B polymerase inhibitors, the synthesis of such compounds, and the use of such compounds for inhibiting HCV NS5B polymerase activity, for treating or preventing HCV infections and for inhibiting HCV viral replication and/or viral production in a cell-based system.

35. 发明公开

EP3055288A1 ANTIDIABETIC TRICYCLIC COMPOUNDS 有权转让
标题翻译：抗糖尿病三环类化合物
公开(公告)号：EP3055288A1
公开(公告)日：2016-08-17
申请号：EP14852689.0
申请日：2014-09-30
申请人： Merck Sharp & Dohme Corp.
发明人： BIFTU, Tesfaye , BIJU, Purakkatle , COLLETTI, Steven L. , CUI, Mingxiang , HAGMANN, William K. , HU, Bin , JOSIEN, Hubert , KAR, Nam Fung , NAIR, Anilkumar , NARGUND, Ravi , SPERBECK, Donald M. , ZHU, Chen
IPC分类号： C07D221/16 , C07D401/12 , C07D401/14 , A61K31/444 , A61K31/438 , A61P3/10
CPC分类号： C07D221/16 , A61K31/435 , A61K31/444 , A61K45/06 , C07D401/12 , C07D405/12
摘要： Novel compounds of the structural formula (I), and the pharmaceutically acceptable salts thereof, are agonists of G-protein coupled receptor 40 (GPR40) and may be useful in the treatment, prevention and suppression of diseases mediated by the G-protein-coupled receptor 40. The compounds of the present invention may be useful in the treatment of Type 2 diabetes mellitus, and of conditions that are often associated with this disease, including obesity and lipid disorders, such as mixed or diabetic dyslip idemia, hyperlipidemia, hypercholesterolemia, and hypertriglyceridemia.
摘要翻译：结构式（I）的新型化合物及其药学上可接受的盐是G蛋白偶联受体40（GPR40）的激动剂，并且可用于治疗，预防和抑制由G蛋白偶联介导的疾病受体40.本发明化合物可用于治疗2型糖尿病以及通常与该疾病相关的病症，包括肥胖和脂质紊乱，例如混合性或糖尿病性血脂异常，高脂血症，高胆固醇血症和高甘油三酯血症。

36. 发明公开

EP3013334A1 SUBSTITUTED BENZOFURAN COMPOUNDS AND METHODS OF USE THEREOF FOR THE TREATMENT OF VIRAL DISEASES 审中-公开
标题翻译：取代的苯并呋喃和方法及其用于病毒病的治疗
公开(公告)号：EP3013334A1
公开(公告)日：2016-05-04
申请号：EP14816866.9
申请日：2014-06-19
申请人： Merck Sharp & Dohme Corp.
发明人： LIU, Hong , DAI, Xing , PALANI, Anandan , HE, Shuwen , NARGUND, Ravi , XIAO, Dong , DANG, Qun , PENG, Xuanjia , LI, Peng
IPC分类号： A61K31/343
CPC分类号： C07D405/14 , A61K31/4439 , A61K31/444 , A61K31/497 , A61K31/4985 , A61K31/501 , A61K31/506 , A61K45/06 , C07D405/04 , C07D413/14 , C07D471/04 , C07D471/14 , C07D487/14 , C07D491/048 , C07D498/04
摘要： The present invention relates to compounds of formula I that are useful as hepatitis C virus (HCV) NS5B polymerase inhibitors, the synthesis of such compounds, and the use of such compounds for inhibiting HCV NS5B polymerase activity, for treating or preventing HCV infections and for inhibiting HCV viral replication and/or viral production in a cell-based system. (I)

37. 发明授权

EP3221343B1 INSULIN RECEPTOR PARTIAL AGONISTS 无效转让
公开(公告)号：EP3221343B1
公开(公告)日：2020-09-16
申请号：EP15807730.5
申请日：2015-11-19
申请人： Merck Sharp & Dohme Corp.
发明人： LIN, Songnian , YAN, Lin , HUO, Pei , PISSARNITSKI, Dmitri , FENG, Danqing , NARGUND, Ravi , ZHU, Yuping , KEKEC, Ahmet , MADSEN-DUGGAN, Christina B. , SHI, Zhi-Cai , WU, Zhicai , MU, Yingjun
IPC分类号： C07K14/62 , A61K38/28

38. 发明公开

EP3209682A1 CO-AGONISTS OF THE GLUCAGON AND GLP-1 RECEPTORS 无效转让
标题翻译： GLUCAGON和GLP-1受体的共同激动剂
公开(公告)号：EP3209682A1
公开(公告)日：2017-08-30
申请号：EP15790398.0
申请日：2015-10-22
申请人： Merck Sharp & Dohme Corp.
发明人： CARRINGTON, Paul, E. , DENG, Qiaolin , NARGUND, Ravi , PALANI, Anandan , TUCKER, Thomas Joseph , WU, Chengwei , BIANCHI, Elisabetta , ORVIETO, Federica , PESSI, Antonello
IPC分类号： C07K14/605 , A61K38/26 , A61K38/28
CPC分类号： A61K38/28 , A61K38/26 , C07K14/605 , A61K2300/00
摘要： Described are peptide analogs of glucagon, which have been modified to be resistant to cleavage and inactivation by dipeptidyl peptidase IV (DPP-IV) and to increase in vivo half-life of the peptide analog while enabling the peptide analog to have relatively balanced agonist activity at the glucagon-like peptide 1 (GLP-1) receptor and the glucagon (GCG) receptor, and the use of such GLP-1 receptor/GCG receptor co-agonists for treatment of metabolic disorders such as diabetes, non-alcoholic fatty liver disease (NAFLD), non-alcoholic steatohepatitis (NASH), and obesity
摘要翻译：描述了胰高血糖素的肽类似物，其已经被修饰以抵抗二肽基肽酶IV（DPP-IV）的切割和失活并且增加肽类似物的体内半衰期，同时使肽类似物具有相对平衡的激动剂活性对胰高血糖素样肽1（GLP-1）受体和胰高血糖素（GCG）受体的应用，以及此类GLP-1受体/ GCG受体共激动剂用于治疗代谢病症例如糖尿病，非酒精性脂肪肝疾病（NAFLD），非酒精性脂肪性肝炎（NASH）和肥胖。

39. 发明公开

EP3013333A1 HETEROCYCLIC COMPOUNDS AND METHODS OF USE THEREOF FOR THE TREATMENT OF HEPATITIS C 有权转让
标题翻译：杂环化合物和方法及其使用C型肝炎的治疗
公开(公告)号：EP3013333A1
公开(公告)日：2016-05-04
申请号：EP14816671.3
申请日：2014-06-19
申请人： Merck Sharp & Dohme Corp.
发明人： HE, Shuwen , LAI, Zhong , DAI, Xing , XIAO, Dong , LONDON, Clare , ZORN, Nicolas , NARGUND, Ravi , PALANI, Anandan , MCCOMAS, Casey, C. , LI, Peng , PENG, Xuanjia
IPC分类号： A61K31/343
CPC分类号： A61K31/454 , A61K31/404 , A61K31/423 , A61K31/4525 , A61K31/4545 , A61K31/496 , A61K31/498 , A61K31/502 , A61K31/5377 , A61K31/55 , A61K45/06 , C07D405/04 , C07D405/14 , C07D413/14 , C07D417/14 , C07D471/04 , C07D487/04 , C07D495/04 , C07D498/04 , C07D513/04 , A61K2300/00
摘要： The present invention relates to compounds of formula I that are useful as hepatitis C virus (HCV) NS5B polymerase inhibitors, the synthesis of such compounds, and the use of such compounds for inhibiting HCV NS5B polymerase activity, for treating or preventing HCV infections and for inhibiting HCV viral replication and/or viral production in a cell-based system.(I)

40. 发明公开

EP2571351A1 DIAZENIUMDIOLATE CYCLOHEXYL DERIVATIVES 有权转让
标题翻译： DIAZENIUMDIOLAT环己基衍生物
公开(公告)号：EP2571351A1
公开(公告)日：2013-03-27
申请号：EP11784021.5
申请日：2011-05-16
申请人： Merck Sharp & Dohme Corp.
发明人： ALI, Amjad , YAN, Lin , HUO, Pei , NARGUND, Ravi
IPC分类号： A01N33/26 , A61K31/13 , A61K31/15
CPC分类号： C07C291/02 , C07B59/001 , C07C2601/14
摘要： A compound having the structure (I) or a pharmaceutically acceptable salt thereof, wherein R
3 is hydrogen, deuterium, -OH, -OC
1-6 alkyl, or halogen; R
8 is hydrogen, deuterium, or C
1-6 alkyl; R
11 and R
12 are independently hydrogen, -C
1-6 alkyl, -OH, -OC
1-6 alkyl, or halogen; R
13 and R
14 are independently -C
1-6 alkyl, -(CH
2 )
1-2 OH, or -OC
1-6 alkyl, or, together with the nitrogen atom to which they are attached, form a 4- to 7-membered heterocyclic ring containing one nitrogen atom and 0 or 1 oxygen atoms, wherein said ring is unsubstituted or mono-, di- or tri-substituted with halogen or -C
1-6 alkyl; R
15 is (CR
1 R
2 )
n C(O)OR
16 , wherein n is 0, 1 or 2, -C(O)NHCH(R
17 )OR
16 , or -C(O)NHCH(R
17 )C(O)NHCH(R
18 )C(O)OR
16 ; R
16 is hydrogen, C
1-6 alkyl, or (CH
2 )
1-2 N+R
19 R
20 R
21 ; R
1 , R
2 , R
4 , R
5 , R
6 , R
7 , R
9 , R
10 , R
17 , R
18 , R
19 , R
20 , and R
21 are independently hydrogen or -C
1-6 alkyl; and stereoisomers thereof, and pharmaceutically acceptable salts thereof, and pharmaceutically acceptable salts of stereoisomers thereof.
摘要翻译：具有结构（I）的化合物或其药学上可接受的盐，其中R 3是氢，氘，-OH，-OC 1-6烷基或卤素; R8是氢，氘或C1-6烷基; R 11和R 12独立地是氢，-C 1-6烷基，-OH，-OC 1-6烷基或卤素; R 13和R 14独立地是C 1-6烷基， - （CH 2）1-2 OH或-OC 1-6烷基，或者与它们所连接的氮原子一起形成含有一个氮的4-至7-元杂环原子和0或1个氧原子，其中所述环是未取代的或被卤素或-C 1-6烷基单取代或二取代或三取代; R 15是-C（O）OH，-C（O）OCH 2 CH 2 N + CH 3）3，其中n是0,1或2，-C（O）NHCH（R 17）OR 16或-C（O）NHCH（R 17）C （O）NHCH（R 18）C（O）OR 16; R16是氢，C1-6烷基或（CH2）1-2N + R19R20R21; R 1，R 2，R 4，R 5，R 6，R 7，R 9，R 10，R 17，R 18，R 19，R 20和R 21独立地为氢或-C 1-6烷基; 及其立体异构体及其药学上可接受的盐及其立体异构体的药学上可接受的盐。

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式